1. McNeil JJ, Piccenna L, Ioannides-Demos LL. Smoking cessation recent advances. Cardiovasc. Drug Ther 2010;24:359-67.
2. Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract 2013;67:469-476.
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008;16:CD006103.
4. Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: a review of the literature. Curr Ther Res Clin Exp 2009;70:35-54.
5. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-1366.
6. Colak C, Parlakpinar H. Reporting In Vivo Experiments: ARRIVE Guidelines-Review. J Turgut Ozal Med Cent 2012;19:128-131.
7. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157:907-921.
8. Uchiyama M, Mihara M. Determination of MDA precursor in tissue by TBA test. Anal Biochem 1978;36: 271-278.
9. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968;25:192-205.
10. Sun Y, Oberley LW, Li YA. Simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
11. Aebi H. Catalase. In: Bergmeyer HU (ed) In methods of enzymatic analysis. New York, NY: Academic Press 1974;673-677.
12. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
13. Wei H, Frenkel K. Relationship of oxidative events and DNA oxidation in Sencar mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993;14:1195-1201.
14. Ciftci O, Aydin M, Ozdemir I, Vardi N. Quercetin prevents 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced testicular damage in rats. Andrologia 2012;44:164-173.
15. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms,and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008;197:371-377.
16. Bolin K, Mark AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy-Cost-utilityresults for Sweden 2003. Respir Med 2008;102:699-710.
17. Coe JW, Brooks PR, Vetelino MG, Coe JW, Brooks PR, Vetelino MG, et al. Varenicline:An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-3477.
18. Dougherty PL. Varenicline: A new pharmaceutical approach to smoking cessation. Nurs Womens Health 2008;12:66-69.
19. Bird ML, Vesta KS. Varenicline-associated acute renal failure. The Annals of Pharmacotherapy 2008;42:1908-1911.
20. Koç A, Erken HA, Koçak FE, Yay A, Güçlü A, Sari E, et al. Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study. Int Urol Nephrol 2015;47:823-829.
21. Woynillowicz AK, Raha S, Nicholson CJ, Holloway AC. The effect of smoking cessation pharmacotherapies on pancreatic beta cell function. Toxicol Appl Pharmacol 2012;265:122-127.
22. Ozbek E, Turkoz Y, Sahna E, Ozugurlu F, Mizrak B, Ozbek M. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int 2000;85:742-6.
23. Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats protective role of melatonin. J Pineal Res 2003;35:85-90.
24. Walker EM, Gale GR. Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 1981;11:397-410.
25. Parlakpinar H, Olmez E, Acet A, Ozturk F, Tasdemir S, Ates B, et al. Beneficial effects of apricot-feeding on myocardial ischemia-reperfusion injury in rats. Food Chem Toxicol 2009;49: 802-808.
26. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
27. Wieland E, Brandes A, Armstrong VW, Oellerich M. Oxidative modification of low density lipoproteins by human polymorphonuclear leukocytes. Eur J Clin Chem Clin Biochem 1993;31:725-731.
28. Sahna E, Parlakpinar H, Ozturk F, Cigremis Y, Acet A. The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. Urol Res 2003;31:188-193.
29. Brüne B, von Knethen A, Sandau KB. Nitric oxide and its role in apoptosis. Eur J Pharmacol 1998;26;351:261-272.
30. Richburg JH. The relevance of spontaneous and chemically induced alterations in testicular germ cell apoptosis to toxicology. Toxicol. Lett. 2000;112-113:79-86.
31. Hegazy R, Salama A, Mansour D, Hassan A. Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition. PLoS One 2016;18;11:e0151486.